Two progressive multiple sclerosis subjects in a high-dose six-patient cohort given ATA188 have seen their disease reverse.
Close analysis of the Parp inhibitor’s pivotal prostate cancer trial raises additional questions over this week’s US approval.
Clinical data are expected soon from Novo Nordisk, Bayer and Sanofi, while Roche and Gilead take aim at ulcerative colitis.
Pivotal ulcerative colitis data on etrolizumab, a dual-action anti-integrin antibody, are due soon, and Roche has Takeda’s Entyvio in its sights.
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?